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Background: Patients with diabetes mellitus have a high risk of atherothrombotic events. Diabetes contributes for
initiation and progression of microvascular and macrovascular complications. Shortened activated partial thromboplastin
time (aPTT) values may reflect hypercoaguable state, which is associated with increased thrombotic risk and adverse
cardiovascular events. Increased level of fibrinogen is common in type II diabetes. The present study was conducted to
study the aPTT and fibrinogen levels in diabetics in a tertiary care Teaching Hospital of Nepal.
Methods: Observational study was performed at out-patients visiting Pathology Department at Tribhuvan University
Teaching Hospital from August 5 to September 7, 2012. Research protocol was approved by Institutional Review Board at
Tribhuvan University Institute of Medicine. Altogether 90 people who came to the hospital during study period and who
met inclusion criteria were selected, out of which 72 were diabetics and 18 were normal controls. Diabetic cases were
identified via verbal interview with patients themselves and review of laboratory findings and diagnosis performed by
their physicians. Diabetics with a diabetic history of more than one year and stabilized with antidiabetic medicines such
as insulin, metformin, glibenclamide, and gliclazide and diabetics with controlled diabetes as revealed by HbA1c in the
range 6.2-7% were taken for the study purpose. Data were analyzed with chi square test and Fischer’s exact test
(when each cell frequency was less than 5) using Statistical Package for Social Sciences 17.
Results: Maximum (53; 73.6%) diabetics and all non-diabetics had aPTT in the range 26–40 seconds. Maximum
(51; 70.8%) patients had fibrinogen beyond 351 whereas all non-diabetics had fibrinogen in the range 151–350. Mean
aPTT values of the diabetic patients and non-diabetic persons were 29.88 ± 4.89 seconds and 32.44 ± 2.25 seconds
respectively. Mean fibrinogen values of the diabetic patients and non-diabetic persons were 388.57 ± 60.90 mg/dL
and 320.89 ± 10.20 mg/dL respectively. Test data identified in results were statistically significant for aPTT (p value 0.000)
and fibrinogen (p value 0.000) between the diabetics and non-diabetics.
Conclusions: Diabetics have an increased level of fibrinogen and relatively shortened aPTT as compared to the
non-diabetic patients.
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Patients with diabetes mellitus have a high risk of ather-
othrombotic events. Many studies have shown a variety of
diabetes mellitus related abnormalities in hemostasis
and thrombosis [1,2]. The diabetic condition contributes
for initiation and progression of microvascular and macro-
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stated.Although modern coagulation diagnostic tests are be-
coming more sophisticated, standard coagulation screening
tests, such as activated partial thromboplastin time (aPTT)
and prothrombin time (PT) are still important basic exami-
nations in clinical laboratories. Shortened aPTT values may
reflect a hypercoaguable state, which is potentially associ-
ated with increased thrombotic risk and adverse cardiovas-
cular events [4,5]. Shortened aPTT may result from an
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[4,6]. Therefore, aPTT can be used to assess the risk of
thromboembolic complications in patients with diabetes
mellitus [4,7].
Plasma fibrinogen levels influence thrombogenesis,
blood rheology, blood viscosity and platelet aggregation.
Epidemiological studies have found a significant association
between fibrinogen levels and insulin levels [8,9]. Markers
of fibrinolysis are abnormal in people with metabolic
syndrome and fibrinolytic dysfunction is markedly increased
in subjects with diabetes mellitus and abdominal obesity
[8,10]. In addition, chronic hyperglycemia and tissue
glycation have marked effects on fibrin structure, clot
generation and resistance to fibrinolysis [8]. Increased
level of fibrinogen is common in non-insulin dependent
diabetes mellitus (NIDDM) patients. In diabetic patients
there is an increased rate of fibrinogen clearance, with
shorter fibrinogen circulating half life [11]. Since free
radicals activate thrombin formation in diabetics, oxidative
stress may represent a possible link between the diabetic
state and hyperfibrinogenaemia [12]. This suggests that
the high level of fibrinogen in plasma will consequently
shorten aPTT and might be a risk marker for cardiovascu-
lar disease because it reflects increased thrombin formation
and therefore a greater possibility that a thrombotic event
will occur.
Although aPTT is assayed for identifying abnormalities
in the factor XII, prekallikrein and high molecular weight
kininogen, intrinsic factors XI, VIII, IX and common factors
X, V, prothrombin and fibrinogen pathways of coagulation,
the present study has been conducted to study the APTT
and fibrinogen levels in patients with type II diabetes
mellitus.Methods
Study site and study population
The study was performed at outpatients visiting Tribhuvan
University Teaching Hospital (TUTH) Pathology Depart-
ment. This was one of the renowned tertiary care teaching
hospitals in Nepal that serves around 575000 outpa-
tients annually. The target population was the diabetics
with a diabetic history of more than one year. The dia-
betic cases were identified via verbal interview with the
patients themselves and the review of the laboratory
findings and diagnosis performed by their physicians.
The control of blood glucose level was determined by
the HbA1c value 6.2-7%. Besides these, normal control
samples were also collected from the patients who did
not have any evidence of diabetes. Altogether 90 people
who came to the hospital during the study period and
who met the criteria selected for the study were chosen
for the study, out of which 72 were diabetics and 18 were
normal controls.Ethical considerations
The research protocol was approved by the Institutional
Review Board at Tribhuvan University Institute of Medi-
cine. The purpose and objectives of the study was explained
to the respondents. The study protocol conformed to
the ethical guidelines of the 1975 Declaration of Helsinki.
Verbal informed consent from each respondent was taken.
Nobody was forced to participate in the study. Confi-
dentiality was maintained throughout research work.
The respondent was allowed to quit if he/she did not want
to participate in the research.
Equipments and materials
Plastic tube with 3.2% trisodium citrate for the collection
of 2 mL blood sample; centrifuge machine; 37°C water
bath; micropipettes 50 microliter and 100 microliter and
disposable tips; glass reaction tubes; automated blood
coagulation analyzer (Sysmex CA–50®); Hemostat APTT
el (human)® and Calcium chloride (CaCl2 0.025 mol/l);
Hemostat fibrinogen (human)®.
Study design and study procedure
Single centric, observational study was performed at
outpatients visiting Pathology Department at Tribhuvan
University Teaching Hospital from August 5 to September
7, 2012. The blood sample collection of Pathology Depart-
ment was chosen for the sample collection. At the time of
collection, a brief interview of the patient was taken to
find out their diabetic history, their blood pressure and
any medicine they were taking. Patients were selected for
the interview via simple random sampling technique. The
purpose of the study was clearly explained to the patients.
Venous blood sample was collected in 3.2% trisodium
citrate vial and aPTT and fibrinogen tests were mea-
sured. The normal range for aPTT and fibrinogen were
26–40 seconds and 151–350 mg/dL respectively in the
laboratory where the study was carried out. The automated
blood coagulation analyzer in the laboratory exhibited
the aPTT and fibrinogen values up to two decimal points
whenever required for accuracy.
Inclusion criteria
All diabetics with a diabetic history of more than one year
and stabilized with antidiabetic medicines such as insulin,
metformin, glibenclamide, and gliclazide were included
for the study. Normal control samples were also collected
from the patients who did not have any evidence of
diabetes for the comparison with tests. Only the diabetic
patients with controlled diabetic status as revealed by HbA1c
in the range 6.2-7% were taken for the study purpose.
Exclusion criteria
Diabetics who did not wish to provide verbal consent for
the participation in the interview were excluded. Diabetic
Table 1 Basic characteristics of study population
Variables Frequency Percentage











Gender of diabetic patients
Male 45 62.5
Female 27 37.5
Gender of non-diabetic patients
Male 10 55.6
Female 8 44.4
(n = 90: case = 72; control = 18) (Mean age of diabetic patient =51.53, SD 8.71
years; mean age of non-diabetic patients =52.72, SD 7.41 years).
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lation therapy such as aspirin or any other medication
which might affect aPTT and fibrinogen were excluded
for the study. Diabetic patients with other complications
were also excluded for the study.
Procedure for aPTT determination
First of all 50 micro litre test plasma was warmed at 37°C
for 5 minutes. At the same time the aPTT reagent and
CaCl2 were also simultaneously incubated. Then 50 micro
litre aPTT reagent was added to the warmed plasma and
mixed and again incubated at 37°C for 3 minutes. After
that 50 micro litre pre-warmed CaCl2 was added. Then
the analyzer read the clotting time of aPTT and displayed
the result in seconds.
Procedure for fibrinogen determination
First of all the test plasma was diluted in imidazole buffered
saline to give a dilution of 1:10. Then 100 micro litre of
diluted plasma was warmed at 37°C for 3 minutes. Then
50 micro litre of thrombin solution was added. After
that the analyzer read the clotting time and quantified
the amount of fibrinogen present in the plasma.
Blood sample collection and principle of automated
blood coagulation analyzer
With an aseptic venipuncture blood sample collection
technique, 2 mL of fasting sample was collected with a
sterile disposable syringe. Into the 3.2% trisodium citrate
vial, 1.8 mL of the collected blood sample was delivered
through the wall and mixed properly without any frothing.
This makes a dilution of 1:9. After mixing gently, the
platelet poor plasma was obtained by centrifuging at
1500 g for 15 minutes. The test was done within 2 hours
of sample collection.
Plasma was incubated for a certain time period, reagent
was added. The sample to which the reagent was added
was then exposed to a wavelength of 660 nm and the
turbidity of the blood during the coagulation process
was detected as the change in the scattered light intensity.
The time recorded after the addition of calcium chloride
was recorded as aPTT.
From the change in light intensity, a coagulation curve
was prepared and coagulation time was found by means
of the percentage detection method. The coagulation time
thus formed was compared to the fibrinogen calibration
chart already set in the analyzer to obtain the amount of
fibrinogen in the plasma.
Data processing and analysis
Data were processed and analyzed using Statistical Package
for Social Sciences (SPSS) version 17; chi square test and
Fischer’s exact test (when each cell frequency was less
than 5) were used for the analysis. A p value < 0.05 wasconsidered significant at 95% confidence interval with
two-sided design.
Results
In the study, there were 48.6% diabetic patients in the
age group 41–50 years and this followed by 34.7% patients
in the age group 51–60 years. The study showed that
55.6% were non-diabetics in the age group 51–60 years.
The study revealed that 62.5% diabetics were males and
55.6% non-diabetics were also males (Table 1).
The study showed that 72% diabetic patients had history
of diabetes of 2–6 years and 56.9% diabetic patients
were taking antidiabetic medications. Among the patients,
68.1% had normal blood pressure (Table 2).
The study found that 73.6% diabetic patients had aPTT
in the range 26–40 seconds whereas 100% of the non-
diabetic persons had aPTT in that range. Maximum
(70.8%) patients had fibrinogen in beyond 351 whereas
100% non-diabetic persons had fibrinogen in the range
151–350. The chi square and Fischer’s exact tests showed
that the test data were statistically significant for aPTT
(p value 0.000) and fibrinogen (p value 0.000) between
the diabetics and non-diabetics (Figure 1).
The chi square and Fischer’s exact tests showed that
there was no significant association between duration of
diabetes mellitus and aPTT of diabetic patients (p value
0.206) and no significant association between duration of
diabetes mellitus and fibrinogen level of diabetic patients
(p value 0.221).
Table 2 Diabetes-related characteristics of the diabetic
patients
Variables Frequency Percentage





Antidiabetic medication used by diabetic patients
No 31 43.1
Yes 41 56.9
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In patient with diabetes mellitus, persistent hypergly-
cemia exposes red blood cells to elevated glucose
concentration, resulting in glycation of hemoglobin, pro-
thrombin, fibrinogen and other protein involved in
clotting mechanisms.
The present study showed that the association of aPTT
with duration of the diabetes was not significant (p > 0.05).
Zhao et al. observed that when diabetic group was
compared with normal group, statistically significant
differences were observed in overall aPTT (p =0.001) [13].
Fibrinogen levels have been shown to be elevated in
type II diabetes mellitus patients [14]. Similarly, Lippi
et al. also observed that there were significantly higherFigure 1 The aPTT and Fibrinogen related characteristics of the
person =29.88 ± 4.89 seconds and 32.44 ± 2.25 seconds respectively;
non-diabetic person =388.57 ± 60.90 mg/dL and 320.89 ± 10.20 mg/dfibrinogen levels and shortened aPTT values in diabetic
patients. The exact biological mechanisms of throm-
bosis in diabetics are likely to be multifactorial and
incompletely understood yet [4]. Korte et al. found that
patients presenting with shortened aPTT values were
in a complex hypercoagulant state and at increased risk
for thromboembolism [15]. Tripodi et al. found that
hypercoaguability detected by shortened aPTT values was
independently associated with venous thromboembolism
and hypothesized that shortened aPTT could be as a
risk matter for venous thromboembolism (VTE) [7].
Shortened aPTTs are generally considered to be laboratory
artifacts arising from problematic venipunctures [16].
Shortened aPTT may result from an accumulation of
circulating activated coagulation factors in plasma caused
by enhanced coagulation activation in vivo [4,6].Study limitation
The study was limited to a single hospital only. The
sample size might not be the exact representatives of
the whole case so as to generalize the findings of the
study. The low ratio of non-diabetic to diabetic patients
was due to the fact that less number of study population
came to the study site during the study period.Conclusions
The patients suffering from type II diabetes mellitus
were found to have an increased level of fibrinogen
and relatively shortened aPTT as compared to the non-
diabetic patients.study population. (Mean aPTT of diabetics and non-diabetic
p value 0.000) (Mean fibrinogen level of diabetics and
L; p value 0.000).
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